… Significant inhibition of tumor growth, in mice … erlotinib approaching the maximum tolerated
dose for the mouse. In contrast, the growth of mutant tumors is inhibited by erlotinib treatment …

… In summary, potentiation of the antitumor efficacy of distinct classes of growth factor
receptor inhibitors by erlotinib may have important clinical implications for the treatment of …

… Most adverse events associated with erlotinib plus gemcitabine treatment in this study
were mild-to-moderate, consistent with previous studies [2-5]. Rash was more frequent with …

… In this study, we investigated the effect of erlotinib treatment on autophagy in 4 NSCLC cell
lines with different EGFR mutation status, in order to understand the possible mechanisms …

… Besides mutations in the EGFR gene that make the target sensitive to gefitinib and erlotinib
treatment, it has been shown that other mutations in the EGFR gene are associated with …

… Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal growth factor
… We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring …

… treatment of metastatic breast cancer, therapy directed at EGFR TK represents a potentially
novel approach. Because erlotinib … pre- and post-treatment with erlotinib. In addition, …

… Dose reduction was based on the patient's tolerability of erlotinib treatment and could occur
at any time during the study as guided by protocol. Dosing suspension was implemented for …

… after initiation of gefitinib or erlotinib was 20 months (95% … Comparison of patients treated
with erlotinib to those treated … respond differently to treatment with gefitinib and erlotinib, we …

… Recurrent cancer was noted in 40 patients, four while receiving erlotinib treatment and 36
after stopping erlotinib (Appendix Table A1, online only). The median time to recurrence after …